Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Revised Financial Guidance

This excerpt taken from the EYE 8-K filed Jan 10, 2007.

Revised Financial Guidance

AMO expects the transaction to be dilutive to 2007 adjusted earnings per share (EPS) and slightly accretive to 2008 adjusted EPS. As a result of this transaction, AMO expects amortization to increase by approximately $30 million on an annualized basis, which would bring the company’s total annual amortization to approximately $70 million or about $0.70 per share on an after-tax basis. For more information, see the “Use of Non-GAAP Measures” section later in this release.  Assuming successful close of the transaction early in the second quarter of 2007, AMO’s financial guidance is as follows:

 

2007

 

2008

 

 

 

Previous

 

With Acquisition

 

 

 

 

 

 

 

 

 

 

 

Revenue (in millions)

 

$1,060 - $1,080

 

$1,150 - $1,175

 

$1,350 - $1,370

 

 

 

 

 

 

 

 

 

Adjusted EPS

 

$1.85 - $2.00

 

$1.40 - $1.55

 

$2.25 - $2.40

 

 

UBS Investment Bank is acting as lead financial advisor and Goldman Sachs is acting as co-financial advisor to AMO.  UBS Investment Bank is acting as lead arranger of a $900 million acquisition facility for AMO.  Bank of America and Goldman Sachs are acting as joint-arrangers of the acquisition facility.  Bank of America is acting as lead financial advisor and JPMorgan is acting as co-financial advisor to IntraLase.  Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal advisor to AMO.  Stradling Yocca Carlson & Rauth is acting as legal advisor to IntraLase.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki